Teplizumab curbs beta-cell death in new-onset type 1 diabetes

02/26/2013 | PhysiciansBriefing.com

Patients with new-onset type 1 diabetes had higher rates of beta-cell death compared with those who had long-standing diabetes and those without diabetes, a study found. However, teplizumab treatment was associated with lower beta-cell death and better beta-cell function in patients with new-onset diabetes, researchers wrote in the journal Diabetes.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX